Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:KURA NASDAQ:MGNX NASDAQ:MIST On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKURAKura Oncology$9.40-1.5%$9.34$5.45▼$12.49$846.91M0.362.22 million shs1.01 million shsMGNXMacroGenics$3.88-6.1%$3.71$1.18▼$4.64$262.52M1.18679,542 shs548,331 shsMISTMilestone Pharmaceuticals$1.29-1.5%$1.65$1.00▼$3.06$163.09M0.951.14 million shs1.12 million shsBeginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKURAKura Oncology-1.47%+6.70%+1.95%+12.04%+44.84%MGNXMacroGenics-6.05%-0.77%-8.71%+30.20%+158.67%MISTMilestone Pharmaceuticals-1.53%+6.61%-14.29%-24.12%-25.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKURAKura Oncology$9.40-1.5%$9.34$5.45▼$12.49$846.91M0.362.22 million shs1.01 million shsMGNXMacroGenics$3.88-6.1%$3.71$1.18▼$4.64$262.52M1.18679,542 shs548,331 shsMISTMilestone Pharmaceuticals$1.29-1.5%$1.65$1.00▼$3.06$163.09M0.951.14 million shs1.12 million shsBeginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKURAKura Oncology-1.47%+6.70%+1.95%+12.04%+44.84%MGNXMacroGenics-6.05%-0.77%-8.71%+30.20%+158.67%MISTMilestone Pharmaceuticals-1.53%+6.61%-14.29%-24.12%-25.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceKURAKura Oncology 2.69Moderate Buy$25.46170.87% UpsideMGNXMacroGenics 2.29Hold$5.5041.75% UpsideMISTMilestone Pharmaceuticals 2.50Moderate Buy$7.25462.02% UpsideCurrent Analyst Ratings BreakdownLatest MGNX, KURA, and MIST Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/15/2026KURAKura Oncology Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$24.006/15/2026KURAKura Oncology Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform$24.006/4/2026KURAKura Oncology Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight6/4/2026KURAKura Oncology CLSASubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$24.006/4/2026KURAKura Oncology Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$24.005/28/2026KURAKura Oncology OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$24.005/28/2026KURAKura Oncology Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$24.005/28/2026KURAKura Oncology CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform5/15/2026MISTMilestone Pharmaceuticals Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell5/14/2026MISTMilestone Pharmaceuticals Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$8.00 ➝ $7.005/8/2026MGNXMacroGenics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 6/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookKURAKura Oncology$67.48M12.37N/AN/A$2.00 per share4.70MGNXMacroGenics$149.50M1.65N/AN/A$0.88 per share4.41MISTMilestone Pharmaceuticals$1.55M103.62N/AN/A$0.39 per share3.31Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateKURAKura Oncology-$278.67M-$3.35N/AN/AN/A-411.19%-141.95%-43.28%8/6/2026 (Estimated)MGNXMacroGenics-$74.62M-$1.10N/AN/AN/A-44.79%-147.80%-28.40%8/13/2026 (Estimated)MISTMilestone Pharmaceuticals-$63.06M-$0.68N/AN/AN/AN/A-339.33%-61.79%8/12/2026 (Estimated)Latest MGNX, KURA, and MIST EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026MGNXMacroGenics-$0.57-$0.58-$0.01-$0.58$15.24 million$20.78 million5/13/2026Q1 2026MISTMilestone Pharmaceuticals$0.06-$0.20-$0.26-$0.20$30.12 million$0.24 million5/12/2026Q1 2026KURAKura Oncology-$0.88-$0.83+$0.05-$0.83$25.97 million$18.27 million3/20/2026Q4 2025MISTMilestone Pharmaceuticals-$0.18-$0.16+$0.02-$0.15$37.52 million$1.55 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthKURAKura OncologyN/AN/AN/AN/AN/AMGNXMacroGenicsN/AN/AN/AN/AN/AMISTMilestone PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioKURAKura Oncology0.096.156.14MGNXMacroGenicsN/A1.901.80MISTMilestone Pharmaceuticals1.619.189.09Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipKURAKura OncologyN/AMGNXMacroGenics96.89%MISTMilestone Pharmaceuticals86.18%Insider OwnershipCompanyInsider OwnershipKURAKura Oncology7.60%MGNXMacroGenics13.60%MISTMilestone Pharmaceuticals5.03%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableKURAKura Oncology13088.77 million82.03 millionOptionableMGNXMacroGenics43063.56 million54.92 millionOptionableMISTMilestone Pharmaceuticals30124.50 million118.24 millionOptionableMGNX, KURA, and MIST HeadlinesRecent News About These CompaniesMilestone Pharmaceuticals Inc. (MIST) Shareholder/Analyst Call Prepared Remarks TranscriptJune 10, 2026 | seekingalpha.comMilestone Pharmaceuticals: Here Comes The Revenue RampJune 9, 2026 | seekingalpha.comMilestone Pharmaceuticals: Taking The Long ViewJune 5, 2026 | seekingalpha.comMilestone Pharmaceuticals Inc (MIST) Q1 2026 Earnings Call Highlights: Strategic Advances Amid ...May 14, 2026 | finance.yahoo.comWhy Milestone Pharmaceuticals Inc.’s (MIST) Stock Is Down 8.42%May 14, 2026 | aaii.comAMilestone Pharmaceuticals Inc. (NASDAQ:MIST) Q1 2026 Earnings Call TranscriptMay 14, 2026 | insidermonkey.comMilestone Pharmaceuticals to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQMay 14, 2026 | globenewswire.comMilestone Pharmaceuticals Inc. (MIST) Q1 2026 Earnings Call TranscriptMay 13, 2026 | seekingalpha.comMilestone Reports Q1 Results, Highlights Initial CARDAMYST SalesMay 13, 2026 | benzinga.comMilestone Reports Q1 Results, Highlights Initial CARDAMYST SalesMay 13, 2026 | benzinga.comMilestone Pharmaceuticals (MIST) Reports Q1 Loss, Lags Revenue EstimatesMay 13, 2026 | zacks.comMilestone Pharmaceuticals Reports Progress on CARDAMYST™ Launch and Financial Performance for Q1 2026May 13, 2026 | quiverquant.comQMilestone Pharmaceuticals Announces First Quarter 2026 Financial Results and Provides Corporate UpdateMay 13, 2026 | globenewswire.comMilestone Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 13, 2026May 6, 2026 | globenewswire.comInsider Selling: Milestone Pharmaceuticals (NASDAQ:MIST) CEO Sells 36,500 Shares of StockApril 21, 2026 | insidertrades.comMilestone Pharmaceuticals Announces RESET-PSVT Registry to Generate Real-World Evidence on CARDAMYST™ (etripamil) Nasal Spray in Patients With PSVTApril 10, 2026 | globenewswire.comMilestone's nasal spray heart drug available via Express ScriptsApril 7, 2026 | ncbiotech.orgNMilestone Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare ConferenceApril 7, 2026 | globenewswire.comMilestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 2, 2026 | globenewswire.comMilestone Pharmaceuticals Announces that CARDAMYST™ (etripamil) Nasal Spray is Available on Express Scripts Commercial National FormulariesMarch 31, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMGNX, KURA, and MIST Company DescriptionsKura Oncology NASDAQ:KURA$9.40 -0.14 (-1.47%) Closing price 06/16/2026 04:00 PM EasternExtended Trading$9.40 0.00 (0.00%) As of 06/16/2026 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.MacroGenics NASDAQ:MGNX$3.88 -0.25 (-6.05%) Closing price 06/16/2026 04:00 PM EasternExtended Trading$3.88 0.00 (0.00%) As of 06/16/2026 07:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.Milestone Pharmaceuticals NASDAQ:MIST$1.29 -0.02 (-1.53%) Closing price 06/16/2026 04:00 PM EasternExtended Trading$1.30 +0.01 (+0.78%) As of 06/16/2026 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Gravity Check: Houston, SpaceX Has a Valuation Problem Okta’s AI Moment May Be Bigger Than Investors Realize Strategy’s Bitcoin Rally Has a Hidden Engine Is Lennar Finally Turning the Corner After Its Housing Slump? Plot Twist: How the $110B Paramount-Warner Deal Rewrites Media AST SpaceMobile Announces Launch Date for Its Next 3 BlueBird Satellites Insiders Sell Top Tech Plays: Should Investors Buy, Sell, or Hold? What's Behind the Social Media Controversy Surrounding IonQ? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
